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Abstract
Background: Inflammatory bowel diseases (IBDs) appear to be modulated by the interaction of pathogen-associated
molecular patterns (PAMPs) derived from intestinal bacteria with their respective innate immune receptors, including Toll-like
receptors (TLRs). We aimed to establish if intestinal concentrations of proinflammatory bacterial ligands of TLR2, TLR4, or TLR5
may be altered in murine IBD models, and to characterize which of the major bacterial groups may contribute to each signal.
Methodology/Principal Findings: PAMPs specific for TLR2 (lipopeptide equivalents), TLR4 (lipopolysaccharide equivalents),
and TLR5 (flagellin equivalents) in human and murine fecal and intestinal samples were quantified using HEK-293 cells
transfected with respective TLRs and calibrated with defined standard PAMPs. The induction of colitis in mice by dextran-
sodium-sulphate treatment significantly increased colonic lipopeptide (fourfold) and LPS equivalent (550-fold)
concentrations, while flagellin equivalent concentrations remained similar. The induction of ileitis by oral infection with
Toxoplasma gondii dramatically increased ileal concentrations of lipopeptide (370-fold), LPS (3,300-fold), and flagellin
equivalents (38-fold), all P,0.01. Analysis of representative strains of the major bacterial groups of the human intestine
revealed that enterobacterial species are likely to be more significant contributors of soluble TLR2 and TLR4 stimulants to
the intestinal milieu than Bacteroides species or Gram-positive Firmicutes.
Conclusions/Significance: We conclude that the induction of colitis or ileitis in mice is associated with significant disease-
specific alterations to the PAMP profile of the gut microbiota.
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Introduction
Inflammatory bowel diseases (IBDs), including ulcerative colitis
and Crohn’s disease, are widely believed to be driven by
inappropriate responses to the intestinal microbiota [1]. Among
the mechanisms by which bacteria may promote inflammatory
signalling, recent evidence suggests that pathogen-associated
molecular patterns (PAMPs) derived from intestinal bacteria may
modulate IBDs via stimulation of their respective innate immune
receptors, including Toll-like receptors (TLRs) [2]. TLRs, like
other innate immune receptors, detect conserved PAMPs that are
expressed not only by pathogenic bacteria, but also commensal
bacteria, and thus serve as key sentinels for the detection of
microbial products. For example, TLRs 2, 4 and 5 are the major
cell-surface sensors of bacterial lipopeptides, lipopolysaccharides
(LPS) and flagellins, respectively, while TLRs 3, 7, 8 and 9 detect
nucleic acid motifs [3].
In most cell types, the detection of PAMPs by their respective
TLR evokes a potent pro-inflammatory response, involving rapid
induction of myeloid-differentiation factor 88 (MyD88) and NF-
kB-dependent signalling pathways, and the resultant expression of
a broad array of pro-inflammatory adhesion molecules, chemo-
kines and cytokines. By contrast, PAMP-recognition by intestinal
epithelial cells has been shown to lead to the promotion of barrier
enhancement, epithelial repair and the secretion of anti-microbial
peptides, rather than overt inflammatory reponses [4–6]. Mech-
anisms such as these therefore enable the healthy gut mucosa to
remain largely uninflammed despite chronic lumenal exposure to
large quantities of potentially pro-inflammatory PAMPs derived
from the host commensal microbiota.
Several lines of evidence suggest that dysregulation of this tol-
erance to intestinal TLR-stimulants, or disruption of the epithelial
barrier separating PAMPs from responsive underlying tissues, may
contribute to the development or perpetuation of IBDs. For
example, although it is well established that the presence of
luminal PAMPs is not sufficient to initiate IBDs in animal models
[7–9], it has been shown that TLR-mediated detection of some
lumenal PAMPs can exacerbate existing disease. Administration of
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LPS or CpG-ODN (a TLR9 agonist) to rabbits or mice was shown
to enhance experimentally-induced colitis or ileitis [8,10].
Likewise, we recently reported that oral administration of the
TLR4 agonist lipid-A aggravated immunopathology in a murine
model of Toxoplasma gondii-induced ileitis [11], and that genetic
deletion of TLR4, or treatment with the LPS scavenger
polymyxin-B, ameliorated disease symptoms in this model [12].
In two models of spontaneous colitis, mice genetically deficient in
IL-10 or intestinal epithelial cell expression of NEMO (IKK-c), it
was shown that additional deletion of the TLR-signalling adaptor
protein MyD88 prevented disease progression [13,14]. Bacterial
flagellin has also been implicated in IBDs, as a functional
polymorphism in TLR5 was shown to negatively correlate with
Crohn’s disease [15] and commensal-derived flagellin has been
identified as a dominant antigen in this disease [16].
Paradoxically, however, there is also evidence that TLRs play a
protective role in gut defence. For example, PAMP-sensing by
intestinal epithelial cells has been reported to induce the expression of
bactericidal and barrier-enhancing mediators [4–6], and deficiency in
TLR2, TLR4 or MyD88 was shown to result in increased mortality
following DSS-induced colitis [17,18]. Deletion of TLR5 (but not
other TLRs or MyD88) was also reported to lead to spontaneous
colitis, but interestingly this was reversed by concurrent deletion of
TLR4 in double knockout animals [19], suggesting that specific
PAMPs can serve as either protective or damaging agents in different
IBD models, depending on the context of their exposure.
Such findings lend useful insight to the observation that marked
shifts in bacterial populations, which could alter the profile of
intestinal PAMP concentrations, have been observed in human
IBDs and in animal models of these diseases. In human subjects,
for example, reductions in bacterial diversity are observed in active
IBD [20], and Gram-negative bacteria, particularly E. coli, have
been reported to accumulate at sites of inflammation [21–24].
Likewise, we showed recently using both culture-dependent and
culture-independent techniques that marked enterobacterial
overgrowth occurs in murine models of T. gondii-induced ileitis
and DSS-induced colitis [11–13].
Taken together, these results suggest that TLR-mediated
recognition of intestinal PAMPs plays a complex but key role in
the modulation of IBD pathology. As very little information is
currently available regarding which bacterial groups may
contribute to the soluble and bacteria-associated PAMP pools in
the intestine, or of how PAMP concentrations in the intestinal
contents may be altered during the course of IBDs, we aimed to
quantify the relative biological activities of PAMPs specific for
TLR2 (lipopeptide-equivalents), TLR4 (lipopolysaccharide-equiv-
alents) and TLR5 (flagellin-equivalents) in human and murine
faecal and intestinal samples, and to establish whether the
concentrations of these agents may be altered in two murine
models of IBDs, T. gondii-induced ileitis and DSS-induced colitis.
Materials and Methods
Ethics Statement
All animal experiments were conducted according to German
animal protection laws (LAGeso Berlin, G0170/04) with approval
from the Charite´-Universita¨tsmedizin ethical committee. Animal
welfare was monitored by daily assessment of total clinical scores
using combined data of weightloss, occurance of blood in stool,
and stool consistence. Faecal samples from healthy human
volunteers were collected with written informed consent, although
as no advertisement, reward, intervention or invasive procedures
were involved, institutional review was not sought for collection of
these samples, according to local ethical guidelines.
Cells and Reagents
Human embryonic kidney (HEK)-293 cells (ECACC Cat no:
85120602) and murine RAW 264.7 macrophages (ECACC
Cat no: 91062702) were cultured in DMEM/10% FCS (Sigma).
Flagellin of Salmonella typhimurium and the synthetic bacterial
lipopeptide analogue Pam3CSK4 were from Invivogen. Escherichia
coli R1 (NCTC-13114) derived LPS (a kind gift of Professor Ian
Poxton, University of Edinburgh), was repurified by phenol re-
extraction to remove TLR2-stimulating lipopeptide contaminants
as described previously [25].
Murine Models of Colitis and Ileitis
For induction of colitis, C57BL/10ScSn mice bred under
specific pathogen-free (SPF) conditions were treated with 3.5%
(wt/vol) dextran-sodium sulphate (DSS, 40,000 kDa, MP Biome-
dicals, Illkirch, France) in drinking water ad libitum for seven days.
Mice received water without DSS for 24 hours before sacrifice
with halothan. Colon contents were then surgically removed under
sterile conditions as described previously [13]. For induction of
ileitis, C57/BL6 mice were infected perorally with 100 Toxoplasma
gondii cysts in 0.3 ml PBS by gavage as described previously [12].
The contents of ,1 cm of the terminal ileum were removed under
sterile conditions after 8 days and resuspended in PBS. Samples
were then processed for measurement of soluble PAMP concen-
trations as described below.
Preparation of Murine and Human Faecal PAMP Extracts
Murine colon or ileal contents were mixed 1:4 (weight:volume)
with sterile phosphate-buffered saline (PBS) and vortexed briefly.
This mixture was then centrifuged at 13,000 g for 20 minutes to
pellet bacteria and other large particles before decanting the
supernatant for filtration using a 0.45 mm filter (Millipore) to yield
sterile-filtered faecal extract (SFE), intended to be representative of
the soluble PAMPs present in the gut lumen. Faecal samples from
six healthy, human volunteers (age 22–33 years, 5 M, 1 F) were
also processed in the same manner, although a separate aliquot of
non-filtered, resuspended material was heat-treated at 100uC for
15 minutes to represent the intact, heat-killed normal flora (HKF),
intended to reflect the insoluble PAMPs present in the intestine.
Sterility of HKF and SFE was verified by streaking on LB-agar
plates. Protein content of SFE samples was assessed by Bradford
assay and adjusted to 2 mg/ml by addition of PBS. SFE
concentration is presented as concentration of protein in SFE
samples throughout.
Measurement of Relative Biological Activities of PAMPs in
HKF and SFE
Transfection of TLR-deficient HEK-293 cells was used to
measure relative biological activities of PAMP-equivalents. Cells
were plated in 96-well plates at 26104 cells per well and
transfected after 24 h using Genejuice (Novagen). Amounts of
construct (prepared as described in [26]) per well were 30 ng of
human TLR2, TLR4 (co-expressing MD-2) or TLR5 (Invivogen),
30 ng of CD14, 20 ng of renilla luciferase-reporter construct and
10 ng of firefly luciferase-reporter construct driven by the NF-kB
dependent E-selectin promoter (pELAM). 3 days after transfec-
tion, cells were challenged in triplicate with indicated concentra-
tions of defined TLR-ligands, whole heat-killed bacteria, HKF,
SFE or sterile-filtered bacterial supernatants for 18 h. NF-kB-
dependent reporter expression was measured using Promega
Dual-Glo reagent and normalised to co-transfected renilla expre-
ssion. Fold induction was calculated relative to cells cultured in
medium alone and a standard curve was prepared by plotting fold
TLR Stimulants in Murine IBDs
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NF-kB induction vs concentration for each standard PAMP. For
determination of relative PAMP abundance in HKF and SFE,
samples were diluted until the induction of reporter occurred
within the linear range of the standard curve. PAMP abundance
was then calculated as ng per g faeces (wet-weight) for HKF, or per
mg protein for soluble extracts. PAMP standards did not induce
signalling in cells expressing heterologous TLRs, or in cells
transfected with CD14 alone ([27] and data not shown).
Notably, because it is has been proposed that diverse ligands
beyond lipopeptide- and LPS-based molecules may also contribute
to signalling via TLRs [28], the TLR-stimulating capacity of each
extract is expressed as a biological activity relative to that of a
chosen standard lipopeptide, LPS or flagellin. For this reason, the
concentration of TLR-stimulants in each sample is presented as
‘‘PAMP-equivalents’’ rather than de facto lipopeptides, LPSs or
flagellins. For example, 2 mg per g ‘‘LPS-equivalent’’ means that
each gramme of the extract has a biological activity equivalent to
that of 2 mg E. coli R1 LPS in terms of its capacity to stimulate
TLR4-signalling, and that this activity may derive from multiple
potential TLR-ligands within the sample.
Characterisation of Molecular Species Responsible for
TLR-Stimulation in SFE
To determine whether lipopeptides, LPS or flagellin may be
responsible for the stimulation of TLR2, TLR4 or TLR5
respectively, SFE was treated with lipases, polymyxin-B or
proteinase-K. For lipase treatment, 10 mg/ml human SFE was
treated with Candida antarctica lipase immobilised to inert acrylic
beads (Sigma) for 18 h at 37uC. Beads were then pelleted by
centrifugation and the supernatant was sterile filtered prior to
assay using HEK-293-TLR2 cells. To examine LPS-signalling,
10 mg/ml human SFE, or 100 ng/ml E. coli LPS, was treated with
10 mg/ml polymyxin-B or 1 mg/ml lipid-IVa for 10 minutes before
measurement of capacity to induce TLR4-signalling using HEK-
293-TLR4 cells. To determine if the TLR5 stimulants in SFE are
of protein origin, human SFE (10 mg/ml), or 500 ng/ml S.
typhimurium flagellin was treated with proteinase-K (Sigma) for 4 h
before enzyme denaturation at 80uC for 10 minutes.
Macrophage Stimulation
RAW 264.7 macrophages were plated at 56104 cells per well of
96-well plates and challenged with indicated dilutions of SFE in
triplicate. Supernatant TNF-a was measured at 4 h by L929
bioassay as described previously [29]. For measurement of IkBa
degradation and p38 MAPK phosphorylation, cells were plated at
86105 cells per well in 6-well plates and treated with 20 mg/mL
SFE from each volunteer for 30 minutes. Cellular lysates were
then separated on 12% polyacrylamide gels, blotted to nitrocel-
lulose membranes and probed with rabbit-anti-human-IkBa
(SantaCruz, sc371), mouse-anti-phospho-p38 MAPK (Cell Signal,
9216S) or rabbit-anti-human-GAPDH (SantaCruz, sc25778).
Preparation of Heat-Killed Bacteria and Supernatants
Strains of bacteria examined were: Eubacterium rectale (A1-86),
Eubacterium hallii (L2-7), Eubacterium cylindroides (T2-87), Butyrivibrio
fibrisolvens (16/4), Ruminococcus obeum-like (Sr1/5), Faecalibacterium
prausnitzii (S3L/3), Megamonas hypermegale (Art12/1), Bacteroides
distasonis (20701), Bacteroides eggerthii (20697) and Bacteroides
thetaiotaomicron (B5482). Bacteroides fragilis (NCTC-9343) and
Bifidobacterium bifidum cells and supernatant were kind gifts of
Professor Ian Poxton (University of Edinburgh). University of
Strathclyde teaching laboratory reference strains of Escherichia coli
(NCTC-13114), Salmonella typhimurium, Pseudomonas aeruginosa,
Klebsiella pneumoniae, Proteus vulgaris, Staphylococcus aureus, Enterococcus
faecalis, Streptococcus pyogenes and Lactobacillus plantarum (NCIMB-
6376) were kind gifts of David McNeill (University of Strathclyde).
Each strain was grown in respective standard broths and
conditions to late log-phase and centrifuged to harvest bacterial
cells (13,000 g for 5 minutes). The remaining supernatant (ie the
growth medium from each culture) was sterile filtered and stored
at 220uC prior to assay. Bacterial cell pellets were then washed
and re-suspended in sterile PBS to an optical density of 1.0 at
600 nm (corresponding to approximately 109 bacteria per ml).
Statistical Analysis
Differences in reporter activity or cytokine levels in treated cells
were compared with untreated cells using one-way ANOVA
followed by Dunnet’s test. Intestinal PAMP concentrations are
reported in the results as medians of absolute values. For statistical
analysis of differences between intestinal PAMP concentrations,
mean log10-transformed values were compared using the Student’s
T-test. Differences were assumed to be significant at P,0.05.
Results
Intestinal PAMP Profile Is Markedly Altered During
T. gondii-Induced Ileitis
To determine whether intestinal PAMP concentrations may be
altered in IBD, we first compared the relative abundances of
TLR2, TLR4 and TLR5 stimulants in the ileal contents of healthy
mice with those of mice in which inflammation of the small
intestine was induced by oral administration of T. gondii [12]. This
protocol, which results in severe Th1-type inflammation of the
small intestine, has been described in detail previously [11,12].
PAMP concentrations in ileal extracts were quantified by
measuring their capacity to induce NF-kB signalling in HEK-
293 cells transfected with TLR2, TLR4/MD2 or TLR5, using
standard curves callibrated with Pam3CSK4, LPS and flagellin,
respectively (examples of typical standard curves are shown in
Figure 1A–C). This analysis revealed that all three classes of
PAMP were of relatively low abundance in the ileum, presumably
reflecting the low bacterial numbers in this part of the gut.
However, the induction of ileitis was associated with dramatically
increased concentrations of each of the PAMPs examined
(Figure 1D–F). The median concentration of lipopeptide-equiva-
lents increased from 26 to 9,694 ng/mg protein (P,0.001), LPS-
equivalents from 16 to 52,688 ng/mg protein (P,0.001), and
flagellin-equivalents from 49 to 1,839 ng/mg protein (P,0.01),
representing fold-increases of ,370x, ,3,300x and ,38x,
respectively.
Colonic PAMP Profile Is Significantly Altered During
DSS-Induced Colitis
We next sought to determine whether intestinal PAMP
concentrations may also be altered in DSS-induced colitis. In
healthy mice, colonic soluble LPS concentrations were similar to
those measured earlier in the terminal ileum. However, lipopep-
tide concentration increased ,40-fold and flagellin increased
,25-fold in the transition from ileum to colon in healthy mice
(Figure 1, 2). The induction of colitis by DSS-treatment further
increased median colonic lipopeptide-equivalent concentrations
from 1,083 to 4,364 ng/mg protein (P,0.05), and LPS-equiva-
lents from 8 to 4,421 ng/mg protein (P,0.001), although colonic
flagellin-equivalents remained not-significantly altered (113 vs
32 ng/mg protein, P = 0.19). These represent fold-changes of
,4x, ,550x and ,0.28x, respectively, following induction of
colitis (Figure 2A–C).
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Determination of Relative PAMP Abundances in Healthy
Human Faecal Microbiota
Wenextmeasured the relative biological activities of PAMPs present
in the heat-killed microbiota derived from faeces of six healthy human
subjects (Figure 3A–C). The median concentration of Pam3CSK4-
equivalent TLR2-stimulants was found to be approximately 10-fold
higher than that of E. coli LPS-equivalent TLR4-stimulants (23 mg per
g faeces vs 1.9 mg per g, P,0.001). Interestingly, the insoluble flagellin
content of the faecal microbiota was found to be highly variable
between subjects, ranging from 0.019 to 41 mg per g (Figure 3A–C).
Figure 1. Effect of T. gondii-induced ileitis on PAMP profile of murine ileal contents. HEK-293 cells were transfected with CD14, NF-kB
sensitive reporter construct and TLR2, TLR4/MD2 or TLR5 and challenged with indicated concentrations of Pam3CSK4, E. coli LPS or S. typhimurium
flagellin, respectively, for 18 h prior to measurement of reporter activation. Typical standard curves are shown with line-fit equations and coefficients
of correlation (A–C). For measurement of PAMP-equivalent concentrations in test samples, appropriate dilutions of samples were performed until
fold-induction of reporter was within the range of the standard curve. SFE was then prepared from ileal contents of uninfected control mice (n = 3) or
from mice in which inflammation of the small intestine was induced by oral administration of T. gondii (n = 5). The relative abundances of Pam3CSK4-
(D), LPS- (E) and flagellin-equivalents (F) present in each SFE sample were quantified and are presented as relative concentrations of Pam3CSK4, E. coli
LPS or S. typhimurium flagellin equivalents.
doi:10.1371/journal.pone.0009125.g001
Figure 2. Effect of DSS-induced colitis on murine colonic PAMP profile. SFE was prepared from colon contents of untreated control mice
(n = 3) or from mice in which colonic inflammation was induced by 7 days DSS-treatment (n = 5). The relative abundances of Pam3CSK4- (A), LPS- (B)
and flagellin-equivalents (C) present in each SFE sample were quantified as described in the Materials and Methods.
doi:10.1371/journal.pone.0009125.g002
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In order to determine whether PAMPs may also exist in
appreciable quantities in the soluble, ie non-bacterial-cell-associ-
ated, form in the human intestine, sterile filtered extracts (SFE)
prepared from faeces of the same subjects were examined. Soluble
PAMP concentrations were found to be similar to the concentra-
tions measured in the insoluble fraction in each case (P= ns). For
example, median concentrations of soluble lipopeptide-, LPS- and
flagellin-equivalents were 19, 5.1 and 0.4 mg per g faeces,
respectively (Figure 3A–C). After adjustment for protein concen-
tration, faeces of healthy human subjects therefore contained
similar concentrations of lipopeptide, but approximately 10-fold
higher LPS (P,0.05) and 10-fold lower flagellin (P,0.05) than the
colon contents of healthy mice (Figure 2).
Characterisation of TLR-Stimulants Present in Human
Soluble Faecal Extract
The biological activity of the soluble PAMPs present in human
SFE was confirmed by the observation that RAW 264.7
macrophages demonstrated TNF-a secretion, IkBa degradation
and p38 MAPK phosphorylation in response to as little as
10 mg/ml SFE in a manner that was quite variable between
subjects (Figure 4A–B). Separation of PAMPs in SFE by non-
reducing SDS-PAGE showed that while TLR5-stimulants were
of relatively high molecular weight (,50–70 kDa), lipopeptides
were typically of lower molecular weight (mainly ,36 kDa), and
TLR4-stimulants could not be detected in gel slice eluates
(Figure 4C).
Next, as it has been suggested that other molecules of microbial,
and even host, origin could also stimulate TLR2 or TLR4
signalling in addition to lipopeptides and LPS [28], we sought to
further clarify which types of molecules may be responsible for
stimulating TLR2, TLR4 and TLR5 signalling in human SFE.
First, as covalent acylation of lipopeptides is required for their
biological activity [30], we treated human SFE with immobilised
lipase. This protocol significantly reduced the TLR2-stimulating
capacity of SFE, suggesting that lipopeptides are a major
contributor to the intestinal pool of soluble TLR2 stimulants
(Figure 5A). We then took two approaches to determine if LPS
may represent the TLR4-stimulating signal observed in SFE.
Treatment of SFE with polymyxin-B, which sequesters LPS from
TLR4/MD2, or lipid-IVa, which competitively binds to TLR4/
MD2 and thereby blocks LPS signalling, both completely blocked
SFE-induced TLR4-signalling (Figure 5B), suggesting that LPS
is the sole TLR4 stimulant present in SFE. Finally, we found
that proteinase-K treatment blocked completely TLR5-signalling
induced by flagellin or SFE, suggesting that the TLR5 stimulant in
SFE is a protein, most likely flagellin (Figure 5C).
PAMP Expression by Cultured Representatives of Major
Gut Bacterial Groups
As the expression of PAMPs specific for TLRs 2, 4 and 5 by
many of the major gut-bacterial groups has not yet been
established, we aimed to characterise which PAMPs may be
expressed by representatives of the major gut-bacterial groups and
related organisms. HEK-293 cells transfected with CD14 and
reporter alone (ie without TLRs) were insensitive to all of the
bacteria examined, indicating the specificity of each TLR-
transfection assay (Figure 6A). As expected, every bacterial strain
examined stimulated robust TLR2-dependent signalling, confirm-
ing the notion that the majority of bacteria express some form of
lipopeptide (Figure 6B). TLR4-dependent signalling was observed
in response to all of the enterobacterial species examined (E. coli, S.
typhimurium, K. pneumoniae and P. vulgaris) (Figure 6C). Notably,
however, no TLR4-dependent signalling was observed in response
to any of the Bacteroides strains examined, including B. thetaiotao-
micron, B. fragilis and B. distasonis. TLR5-dependent signalling was
observed in response to the expected motile Gram-negative
bacteria (E. coli, S. typhimurium, P. aeruginosa), but also to Eubacterium
rectale and Butyrivibrio fibrisolvens, suggesting that flagella of motile
Gram-positive organisms present in the gut may also stimulate
TLR5 signalling (Figure 6D).
Comparative Shedding of Soluble PAMPs by
Gram-Negative and Gram-Positive Organisms
As it is possible that soluble PAMPs may be more likely to cross
damaged epithelium to stimulate responsive underlying tissues
than PAMPs that remain attached to whole bacteria, we next
aimed to determine which major classes of bacteria may
contribute to the soluble PAMP pools in the gut. We first
confirmed that each bacterial strain examined stimulated
macrophage TNF-a production in response to direct contact with
intact organisms (Figure 7A). However, while filter-sterilised
culture supernatants of enterobacterial species such as E. coli, S.
typhimurium and P. aeruginosa stimulated macrophage TNF-a
production at dilutions from 1:1,000 to 1:10,000, those of four
Gram-positive organisms (L. plantarum, B. bifidum, E. faecalis and S.
aureus), or the Gram-negative B. fragilis, stimulated macrophages
only at a dilution of 1:10, or not at all (Figure 7B). Soluble
stimulants of TLR4 and TLR5 were found to be shed by E. coli, S.
Figure 3. Relative abundance of PAMP-equivalents in normal human faecal flora. The relative abundances of PAMP-equivalents specific
for TLR2 (A), TLR4 (B) and TLR5 (C) were measured in the heat-killed faecal flora from six healthy human subjects (insoluble fraction), or in SFE (soluble
fraction) from the same subjects, using TLR-transfectants as described in the Materials and Methods.
doi:10.1371/journal.pone.0009125.g003
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typhimurium and P. aeruginosa, but not B. fragilis or the Gram-positive
organisms examined (Figure 7C). Next, using TLR2-transfectants
to examine bacterial shedding of lipopeptides, we found that while
the enterobacterial species examined are prolific shedders of
lipopeptide, Gram-positive organisms released little or no soluble
TLR2-stimulants into their surroundings and B. fragilis displayed
an intermediate phenotype (Figure 7D).
Discussion
It is now widely accepted that the destructive cycles of
inflammation observed in IBDs are potentiated by inappropriate
responses towards the host intestinal microbiota [1]. However, it is
not yet clear how the gut remains tolerant of the inflammatory
molecules expressed by the commensal microbiota in health, nor
why this tolerance should become broken during episodes of disease.
Recent evidence suggests that the stimulation of Toll-like receptors
(TLRs) by PAMPs expressed and released by intestinal bacteria may
contribute to the propagation of IBDs [2,7–12,31,32], leading to the
suggestion that elevated intestinal PAMP concentrations could
represent a risk factor for disease progression [10–12,32]. As very
little information is currently available regarding PAMP concen-
trations in the luminal contents of the healthy and diseased gut, or of
which major bacterial groups may contribute to the intestinal
PAMP pools, we sought to employ a novel bioassay-based approach
to address these outstanding questions.
Our results reveal for the first time that the induction of colitis
or ileitis in mice is associated with marked increases in the luminal
concentrations of PAMPs specific for TLR2, TLR4 and/or TLR5.
Moreover, we found that these changes were disease-specific; ileitis
being associated with marked increases in concentrations of
lipopeptide-, LPS- and flagellin-equivalents while colitis was
associated with a modest increase in lipopeptide concentrations,
a large increase in LPS and no change to flagellin concentrations.
Such marked differences in intestinal PAMP concentrations are
Figure 5. Characterisation of TLR-stimulants present in human
soluble faecal extract. (A) Human SFE (10 mg/ml) was treated with
immobilised lipase for 18 h at 37uC, and then assayed for potential to
stimulate TLR2 signalling in HEK-293-TLR2 cells. (B) Human SFE (10 mg/
ml), or 100 ng/ml E. coli LPS, was treated with 10 mg/ml polymyxin-B or
1 mg/ml lipid-IVa for 10 minutes before addition to HEK-293-TLR4 cells
to measure capacity to induce TLR4-signalling. (C) Human SFE (10 mg/
ml), or 500 ng/ml S. typhimurium flagellin was treated with proteinase-K
for 4 h before enzyme denaturation at 80uC for 10 minutes, before
application to HEK-293-TLR5 cells to measure capacity to induce TLR5-
signalling.
doi:10.1371/journal.pone.0009125.g005
Figure 4. Biological activity of soluble PAMPs present in normal
human faeces. (A) RAW macrophages were challenged with 1, 10 or
100 mg/ml SFE of six healthy subjects and TNF-a was measured at 4 h.
Mean +/2 SD shown. (B) RAWmacrophages were challenged with 20 mg/
ml sterile-filtered extract (SFE) of 5 healthy human volunteers.
Degradation of IkBa and phosphorylation p38 MAPK were examined at
30 minutes by western blot. (C) SFE (20 mg total protein) of three healthy
subjects was separated by non-reducing SDS-PAGE and PAMPs were
eluted from gel-slices corresponding to indicated molecular weight
ranges in PBS. HEK-293 cells transfected with TLR2, TLR4/MD2 or TLR5
were challenged with each eluate diluted 1:25 in culture medium.
Responses are displayed as mean fold induction of NF-kB reporter
(pELAM) +/2 SD. ** P,0.01 vs cells cultured in medium alone.
doi:10.1371/journal.pone.0009125.g004
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suggestive of major shifts in the relative abundances of the
bacterial groups that make up the intestinal flora. Accordingly,
many previous studies have reported that the microbiota can
change markedly during IBDs in human subjects and in animal
models [20–24]. In particular, with respect to the specific models
examined here (ie T. gondii-induced ileitis and DSS-induced colitis),
we have shown previously using both culture-dependent and
culture-independent methods that a reduction in bacterial
diversity and a dramatic increase in the numbers of enterobacterial
species occurs in both conditions [11–13].
The relevance of the latter finding is highlighted by the present
study, as we show that enterobacterial species are likely to
represent not only dominant contributors to the pool of soluble
TLR4 stimulants in the gut, but also major contributors to the
pools of soluble pro-inflammatory and TLR2-stimulating agents in
the gut. This conclusion is drawn from the observation that several
members of the other numerically major Gram-negative group,
Bacteroides species, did not stimulate TLR4-signalling (Figure 6C).
Moreover, we found that the shedding of pro-inflammatory
stimulants by enterobacterial species was several orders of
magnitude higher than that observed from Bacteroides species and
Gram-positive commensal organisms such as Lactobacilli and
Bifidobacteria (Figure 7B, D). Taken together, these findings suggest
that despite their numerically minor presence in the gut, the
enterobacteria may nevertheless represent prominent contributors
to the intestinal pools of potentially pro-inflammatory agents. The
in vitro and in vivo findings of the present study therefore support
previous observations of a large expansion of enterobacterial
numbers in both DSS-induced colitis and T. gondii-induced ileitis
[11–13]. In particular, our previous culture analysis of the
microbiota of the inflammed colon suggested that numbers of
Bacteroides/Prevotella spp., enterococci, clostridia and lactobacilli
were not significantly altered by DSS-treatment, while enterobac-
terial species expanded by several orders of magnitude, further
suggesting that the increase in TLR2 and TLR4 stimulants is
driven by the overgrowth of enterobacterial species, rather than
other groups [13]. In the T. gondii-induced ileitis model, 16S gene
sequence analysis revealed that ileal lactobacilli, bifidobacteria and
clostridia disappeared and were replaced with enterobacterial and
bacteroides species, suggesting that enterobacterial overgrowth
drives not only the increase in TLR2 and TLR4 stimulants in this
model, but also the increase in TLR5-stimulants [12].
It should be noted that the PAMP-profiling assay we have
described has specific advantages and limitations in comparison
with alternative methods of examining alterations to the intestinal
microbiota. For example, although the assay is culture-indepen-
dent, requires no knowledge of target organism DNA-sequences
and is not biased towards particular groups arising from primer
Figure 6. Profiles of TLR-stimulation Induced by representative gut bacterial strains. Heat-killed bacteria of indicated species were applied
to HEK-293 cells transfected with CD14, NF-kB sensitive reporter construct and TLR2, TLR4/MD2 or TLR5 at a concentration of ,107 cells per ml.
Responses are displayed as mean fold induction of NF-kB reporter (pELAM) +/2 SD relative to cells cultured in medium alone. * P,0.05 vs medium
alone.
doi:10.1371/journal.pone.0009125.g006
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design, cloning efficiency or antibody-specificity, it cannot provide
information regarding specific groups or species of bacteria or
the exact molecular species contributing to each TLR-signal. For
this reason, and as there is some debate as to the diversity of
ligands that may be recognised by TLR2 and TLR4 [28], we
aimed to clarify which types of molecules may be responsible
for the stimulation of these TLRs in SFE. Since both lipid-IVa
and polymyxin-B completely blocked TLR4 signalling induced
by SFE, it seems likely that LPS is the only TLR4 stimulant
present in SFE (Figure 5B). However, as we found that lipases
blunted, but did not eliminate, the TLR2-signal induced by
SFE (Figure 5A), we cannot exclude the possibility that other
proposed TLR2 stimulants, such as lipoteichoic acid or Bacteroides
LPS may also contribute to the TLR2-signal induced by SFE
[33,34]. Thus, although we note that others have proposed that
contaminating lipopeptides may account for the previously
reported TLR2-stimulating properties of peptidoglycan and
lipoteichoic acid [35,36], we refer to the TLR-stimulants
measured in each assay as ‘‘PAMP-equivalents’’, rather than de
facto lipopeptides or lipopolysaccharides.
A key question that remains to be addressed in future studies is
whether increased concentrations of luminal PAMPs serve merely
as markers, or as mediators of IBDs. Evidence that they may serve
as disease mediators is present in our earlier observations that oral
administration of E. coli lipid-A markedly promotes T. gondii-
induced ileitis in mice, while neutralisation of intestinal LPS by
treatment with polymyxin-B reduced the severity of ileitis [11,12].
Likewise, rectal administration of LPS was shown to promote
colitis in rabbits [8], and administration of the TLR9 agonist
CpG-ODN enhanced DSS-induced colitis in mice [10]. Further-
more, rectally applied S. typhimurium flagellin was found to
aggravate colonic inflammation and increase mortality in DSS-
induced colitis [37]. However, the data obtained from studies of
mice deficient in TLRs suggest a more complex role for PAMP
recognition in the gut, as both barrier protective [4–6,17–19] and
pro-inflammatory roles [7,8,11–16,32] for TLR-mediated PAMP
recognition in the gut have been reported.
One possible way of conciliating these views is to suggest that
while PAMP sensing by epithelial cells serves to enhance barrier
function, if the barrier eventually fails and PAMPs reach the more
sensitive underlying cells and tissues, inflammation may be
triggered to protect the host from translocating bacteria. This
notion is supported by the fact that while the intact colon is largely
unresponsive to exogenously applied flagellin, LPS or lipoteichoic
acid [9,37–39], when the epithelial barrier is disrupted by agents
such as DSS, diverse PAMPs can trigger overt inflammation and
damage [10–12,37,38]. Furthermore, as we found that high
concentrations of PAMPs are generated in the ileum of T. gondii-
infected mice, yet colonic inflammation is not observed despite the
fact that these PAMPs should pass to the colons of these mice, our
data further support the notion that even very high concentrations
of PAMPs are not alone sufficient to induce intestinal inflamma-
tion when the epithelial barrier is intact. Studies involving cell-type
specific deletion of TLRs, rather than systemic knockouts as
currently reported, will likely be required to shed further light on
this complex issue.
Figure 7. Soluble PAMP secretion by Gram-positive and Gram-negative organisms. (A) TNF-a release was measured from RAW
macrophages exposed to whole heat-killed bacteria from a panel of representatives (Gram -ve: E. coli (Ec), S. typhimurium (St), P. aeruginosa (Pa), B.
fragilis (Bf); Gram +ve: B. bifidum (Bb), E. faecalis (Ef), L. plantarum (Lp), S. aureus (Sa)), at a concentration of ,107 bacteria per ml. (B) Serial ten-fold
dilutions of sterile-filtered supernatants from each bacterial culture were made in DMEM/10% FCS, added to RAW macrophages in triplicate and TNF-
a release was measured at 4 h. (C) HEK-293 cells transfected with TLR4/MD2 or TLR5, were challenged with sterile filtered growth supernatants
(1:100). (D) HEK-293 cells transfected with TLR2 were challenged with 10-fold serial dilutions of each sterile-filtered supernatant. Data shown are
representative of at least three independent experiments. * P,0.01 vs cells cultured in medium alone.
doi:10.1371/journal.pone.0009125.g007
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In summary, we conclude that while the healthy gut contains
appreciable quantities of soluble ligands of TLR2, TLR4 and
TLR5, the relative abundances of stimulants of these receptors can
increase dramatically during the course of murine IBDs. Future
studies are warranted to establish whether such alterations to
PAMP profiles are also observed in human IBDs, such as
ulcerative colitis and Crohn’s disease, and whether such alterations
serve as markers or as mediators of these diseases. If the latter
turns out to be evident, studies are also warranted to investigate
whether normalisation of intestinal PAMP concentrations may
possess therapeutic potential for these diseases.
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